A Blueprint for GMP-Compliant Generative AI

Generative AI (Gen AI) is moving quickly from pilot projects into real pharmaceutical workflows, promising faster documentation, smarter knowledge retrieval, and relief from the routine tasks that consume so much expert time. In Good Manufacturing Practice (GMP) environments, however, the very qualities that make GenAI appealing, its adaptability and its ability to generate fresh content on demand, are also what regulators find hardest to reconcile with a framework built on reproducibility and control.  

Why GenAI Sits Uneasily with GMP 

Classical GMP computer systems are deterministic: identical inputs return identical outputs, and that predictability is what makes validation possible in the first place. Large language models work differently, sampling from probability distributions so that the same underlying question can produce subtly different answers depending on context, metadata, or system-level details. In a setting where every decision affecting product quality must be defensible on demand, that variability quickly becomes a design problem rather than a minor quirk.  

The current draft of EU GMP Annex 22 reflects exactly this concern, permitting only static models with fixed outputs in validated critical workflows and confining adaptive or generative systems to low-risk tasks under human oversight​¹​. The position is not final, though. In mid-2026, the EMA GMP/GDP Inspectors Working Group opened a multistakeholder discussion on how adaptive AI could be accommodated within a risk-based Annex 22​²​, drawing on ICH Q9(R1) lifecycle principles​³​ to shape what a workable middle ground might look like.  

Getting the Discipline Right 

Introducing GenAI into GMP has less to do with the model itself than with the discipline built around it, and in practice, that discipline rests on three connected ideas.  

1. The first is a clearly bounded context of use, where the task, the data, and the degree of autonomy are all set out in advance, so that in high-risk areas such as quality release, the model remains firmly advisory and a qualified reviewer takes the final call. This aligns with the human oversight principles of the EU Artificial Intelligence Act (Regulation 2024/1689)​⁴​.
2. The second is traceability that fits the technology, which means capturing inputs, outputs, and user interactions during operation while recording model and training data versioning in the CSV and design documentation under change control. Explainability techniques, from confidence scoring to references back to source content for LLMs, then give reviewers something concrete to point to when an inspector asks how a particular recommendation was reached.
3. The third is controlled lifecycle management, with version-locked deployments, defined change control, and continuous monitoring for output drift, so that updates stay auditable and predictable instead of becoming a reason to freeze innovation altogether.  

Learn How to Validate NGS Workflows in GMP 

Where Genedata Selector Fits In 

These principles become particularly relevant in next-generation sequencing (NGS), where decisions related to GMP rely on large and complex datasets that must be structured, traceable, and scientifically interpretable. Genedata Selector^® provides an analysis environment that serves as a digital infrastructure for NGS-based decision-making. It consolidates metadata, raw and processed sequencing data, as well as datasets from metabolomics and proteomics within a unified ecosystem. This setup creates an AI/ML-ready data layer that supports predictive modeling, allowing teams to avoid working with fragmented files, disconnected systems, or isolated assay outputs. 

Genedata Selector supports this foundation by connecting sequencing instruments with electronic lab notebooks (ELN), laboratory information management systems (LIMS), bioprocess data, and multi-omics information. It automates NGS workflows through configurable Playbooks, guiding processes from sample registration to analysis, review, and reporting. This results in a FAIR database that facilitates statistical modeling, interactive dashboards, AI-assisted scientific reasoning, and predictive analytics. Through its MCP server, AI systems can access and reason over structured scientific data within Genedata Selector, enabling natural-language querying and AI-assisted exploration of complex datasets while maintaining governance and traceability. 

By integrating NGS, multi-omics, sample context, and process context, the platform helps bridge the gap between cell-based product research and manufacturing. This integration strengthens the foundation for CQA assessment, process performance analysis, quality control decision support, and the prediction of potential bioprocess issues. Consequently, it supports faster development timelines, greater scalability, and reduced risks from discovery to commercial production. 

The Takeaway